GemVax & KAEL Co Ltd

As of March 31, 2026, GemVax & KAEL Co Ltd carries a market capitalization of 1.49T, placing it among publicly traded companies globally. Its enterprise value stands at 1.52T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, GemVax & KAEL Co Ltd has 43.95M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 16.55, and the price-to-book ratio stands at 18.48.

As of March 31, 2026, GemVax & KAEL Co Ltd trades at an EV/EBITDA multiple of 149.12 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 17.41 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 254.80 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.52T versus a market cap of 1.49T, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, GemVax & KAEL Co Ltd maintains a current ratio of 1.18, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 71.93, indicating elevated leverage, while an interest coverage ratio of 1.60 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, GemVax & KAEL Co Ltd posted a negative return on equity (ROE) of -6.43, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.34, reflecting losses generated across the asset base. The company generates approximately 420.26M in revenue per employee across its workforce of 208.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.40 indicates how many times GemVax & KAEL Co Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, GemVax & KAEL Co Ltd recorded 439.57M in income tax expense. The company reported a pretax loss of -3.51B and -3.94B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, GemVax & KAEL Co Ltd's stock has declined approximately 79.91% over the past 52 weeks. The 50-day moving average sits at 10,550.60, while the 200-day moving average is 21,141.75.

Over the twelve months ended March 31, 2026, GemVax & KAEL Co Ltd generated 87.41B in revenue and converted that into -3.94B in net income, yielding earnings per share of -92.57. EBITDA reached 10.20B, while operating income came in at 5.74B.

As of March 31, 2026, GemVax & KAEL Co Ltd holds 28.66B in cash and equivalents against 58.07B in total debt, resulting in a net debt position of 33.62B. Total book value stands at 80.73B, with working capital of 8.22B providing operational flexibility.

GemVax & KAEL Co Ltd produced -639.57M in operating cash flow over the twelve months ended March 31, 2026. After subtracting -2.45B in capital expenditures, free cash flow totaled -3.09B - equivalent to -72.49 per share.

Over the twelve months ended March 31, 2026, GemVax & KAEL Co Ltd posted a gross margin of 41.05, reflecting its pricing power and cost economics. The operating margin of 6.57 and net profit margin of -4.51 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -0.21: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.01, meaning GemVax & KAEL Co Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of March 31, 2026, GemVax & KAEL Co Ltd has an Altman Z-Score of 9.40, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.